NO20014013L - 16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem - Google Patents

16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem

Info

Publication number
NO20014013L
NO20014013L NO20014013A NO20014013A NO20014013L NO 20014013 L NO20014013 L NO 20014013L NO 20014013 A NO20014013 A NO 20014013A NO 20014013 A NO20014013 A NO 20014013A NO 20014013 L NO20014013 L NO 20014013L
Authority
NO
Norway
Prior art keywords
halogen
processes
preparation
pharmaceutical use
epothilone derivatives
Prior art date
Application number
NO20014013A
Other languages
English (en)
Other versions
NO20014013D0 (no
Inventor
Ulrich Klar
Werner Skuballa
Bernd Buchmann
Wolfgang Schwede
Michael Schirner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19908765A external-priority patent/DE19908765A1/de
Priority claimed from DE19954230A external-priority patent/DE19954230A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20014013D0 publication Critical patent/NO20014013D0/no
Publication of NO20014013L publication Critical patent/NO20014013L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
NO20014013A 1999-02-18 2001-08-17 16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem NO20014013L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19908765A DE19908765A1 (de) 1999-02-18 1999-02-18 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A DE19954230A1 (de) 1999-11-04 1999-11-04 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
PCT/EP2000/001333 WO2000049021A2 (de) 1999-02-18 2000-02-18 16-halogen-epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung

Publications (2)

Publication Number Publication Date
NO20014013D0 NO20014013D0 (no) 2001-08-17
NO20014013L true NO20014013L (no) 2001-10-18

Family

ID=26052117

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014013A NO20014013L (no) 1999-02-18 2001-08-17 16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem

Country Status (28)

Country Link
US (3) US6610736B1 (no)
EP (1) EP1150980B1 (no)
JP (1) JP2002537301A (no)
KR (1) KR100718616B1 (no)
CN (1) CN1209360C (no)
AR (1) AR022636A1 (no)
AT (1) ATE370946T1 (no)
AU (1) AU3156700A (no)
BG (1) BG105802A (no)
BR (1) BR0008331A (no)
CA (1) CA2361278A1 (no)
CZ (1) CZ20012951A3 (no)
DE (1) DE50014587D1 (no)
EA (1) EA009206B1 (no)
EE (1) EE200100431A (no)
ES (1) ES2291194T3 (no)
HK (1) HK1044945A1 (no)
HR (1) HRP20010677A2 (no)
HU (1) HUP0105478A3 (no)
IL (1) IL144519A0 (no)
MX (1) MXPA01008328A (no)
NO (1) NO20014013L (no)
NZ (1) NZ513268A (no)
PL (1) PL349863A1 (no)
SK (1) SK11852001A3 (no)
TW (1) TWI285645B (no)
WO (1) WO2000049021A2 (no)
YU (1) YU59001A (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367057B1 (de) 1996-11-18 2008-09-17 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilone E und F
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU9340998A (en) * 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
EP1353667A1 (en) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Parenteral formulations containing epothilone analogs
ATE389401T1 (de) 2001-01-25 2008-04-15 Bristol Myers Squibb Co Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
MXPA03007394A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
JP2004522771A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー 治療抵抗性腫瘍の処置用エポチロン誘導体
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4791183B2 (ja) * 2002-08-23 2011-10-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロン、その中間体、類似体の合成およびその使用
RU2462463C2 (ru) * 2002-08-23 2012-09-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения
RS20050235A (en) 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
CA2588400A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising ixabepilone, and preparation thereof
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN101535492A (zh) 2005-02-11 2009-09-16 南加州大学 表达含有二硫键的蛋白质的方法
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20070014978A1 (en) * 2005-07-18 2007-01-18 Anthony Poloso Method of flame blocking and articles made therefrom
WO2007130501A2 (en) * 2006-05-01 2007-11-15 University Of Southern California Combination therapy for treatment of cancer
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
EP2065054A1 (en) * 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
AU2014283185B2 (en) 2013-06-21 2019-05-02 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353732A3 (de) * 1988-08-05 1991-11-06 Ciba-Geigy Ag Neue Fluorolefine, Verfahren zu deren Herstellung und deren Verwendung
JP2685521B2 (ja) 1988-08-05 1997-12-03 株式会社日立製作所 車両用換気装置
DE69009962T2 (de) * 1989-12-27 1994-12-15 Monsanto Co Substituierte Pyridin-Verbindungen.
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
AU9340998A (en) * 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
MXPA01008328A (es) 2002-06-04
DE50014587D1 (de) 2007-10-04
EA200100826A1 (ru) 2002-02-28
US20050187270A1 (en) 2005-08-25
YU59001A (sh) 2005-07-19
AR022636A1 (es) 2002-09-04
CA2361278A1 (en) 2000-08-24
NZ513268A (en) 2004-05-28
AU3156700A (en) 2000-09-04
CN1341115A (zh) 2002-03-20
SK11852001A3 (sk) 2002-04-04
KR100718616B1 (ko) 2007-05-16
ATE370946T1 (de) 2007-09-15
WO2000049021A2 (de) 2000-08-24
US6610736B1 (en) 2003-08-26
EE200100431A (et) 2002-12-16
EP1150980B1 (de) 2007-08-22
CN1209360C (zh) 2005-07-06
KR20010102215A (ko) 2001-11-15
BG105802A (bg) 2002-03-29
WO2000049021A3 (de) 2000-12-28
EP1150980A2 (de) 2001-11-07
HK1044945A1 (en) 2002-11-08
TWI285645B (en) 2007-08-21
PL349863A1 (en) 2002-09-23
EA009206B1 (ru) 2007-12-28
HUP0105478A2 (en) 2002-06-29
BR0008331A (pt) 2002-01-29
NO20014013D0 (no) 2001-08-17
JP2002537301A (ja) 2002-11-05
HUP0105478A3 (en) 2002-08-28
CZ20012951A3 (cs) 2001-11-14
US20040014978A1 (en) 2004-01-22
HRP20010677A2 (en) 2005-06-30
ES2291194T3 (es) 2008-03-01
US6930102B2 (en) 2005-08-16
IL144519A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
NO20014013L (no) 16-halogen-epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
HUP0105414A3 (en) Pyrrolo-isoquinoline, azepino- and diazepino-indole derivatives, their use and pharmaceutical compisitions containing them
DK1117645T3 (da) Arylsubstituerede propanolaminderivater, fremgangsmåder til fremstilling deraf, lægemidler indeholdende disse forbindelser og anvendelse deraf
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20014487D0 (no) Bisykliske heterosykler, farmasöytiske blandinger inneholdende disse forbindelsene og fremgangsmåter forfremstilling av dem
NO20016277D0 (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske formuleringer
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
DK1112251T3 (da) Azetidinderivater, deres fremstilling og medikamenter indeholdende disse derivater
NO20024281D0 (no) Indolderivater, fremgangsmåte for fremstilling av de samme og anvendelse derav
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
HUP0201711A3 (en) N-indanyl-benzamide derivatives, method for their production, their use and pharmaceutical preparations containing them
NO20035220D0 (no) Karboksamidsubstituerte fenylureaderivater og fremgangsmåter for fremstilling av disse som legemidler
NO20020687L (no) 3(5)-ureido-pyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
IS5353A (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
NO20023161D0 (no) Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem
NO20016038L (no) Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme
NO20013900L (no) Epotilonderivater, fremgangsmåter for fremstilling av disse og farmasöytisk anvendelse av dem
NO20016404D0 (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20014803L (no) Pyrido-tieno-diazepiner, fremgangsmåte for fremstilling derav og farmasöytiske blandinger inneholdende dem
NO20013878L (no) (1-fenacy-3-fenyl-3-piperidylety)piperidinderivater, fremgangsmåte for fremstilling derav og farmasöytiske preparaterinneholdende de samme
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application